miR-566 inhibitor

miR-566 inhibitor refers to a class of experimental RNA-based therapeutics, typically antisense oligonucleotides, designed to silence or antagonize the function of microRNA-566 (miR-566). In the context of oncology, particularly glioblastoma multiforme (GBM), miR-566 is identified as an oncomiR that promotes epithelial-mesenchymal transition (EMT) and tumor cell invasion. The mechanism of action involves the inhibition of miR-566, which directly targets and suppresses the von Hippel-Lindau (VHL) tumor suppressor gene. By neutralizing miR-566, the inhibitor restores VHL expression, which subsequently leads to the suppression of the β-catenin/Tcf-4 signaling pathway. This restoration of the miRNA-VHL-β-catenin axis results in reduced invasive and metastatic potential in glioma cells. Currently, miR-566 inhibitors are primarily utilized in preclinical research settings to explore therapeutic strategies for malignant brain tumors.

Other names

anti-miR-566anti-miR566anti-miR 566miR-566 antagomirmiR566 antagomirmiR 566 antagomirmicroRNA-566 inhibitormicroRNA566 inhibitormicroRNA 566 inhibitor